

Global Tumour Neoantigens Market Growth 2022-2028

<https://marketpublishers.com/r/G976339358E0EN.html>

Date: December 2022

Pages: 103

Price: US\$ 3,660.00 (Single User License)

ID: G976339358E0EN

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

Tumor neoantigens, as their name implies, are antigens that are not expressed in normal tissues but are expressed only in tumor tissues, including those produced by the integration of oncogenic viruses into the genome and mutant proteins, and neoantigens are not only highly specific but also strongly immunogenic because of their unselected thymus negative screening.

The global market for Tumour Neoantigens is estimated to increase from US\$ million in 2021 to reach US\$ million by 2028, exhibiting a CAGR of % during 2022-2028. Keeping in mind the uncertainties of COVID-19 and Russia-Ukraine War, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.

The APAC Tumour Neoantigens market is expected at value of US\$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.

The United States Tumour Neoantigens market is expected at value of US\$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.

The Europe Tumour Neoantigens market is expected at value of US\$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.

The China Tumour Neoantigens market is expected at value of US\$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.

Global key Tumour Neoantigens players cover Achilles Therapeutics plc, Advaxis

Immunotherapies, Genocea, Gradalis, Inc and Gritstone bio, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.

Report Coverage

This latest report provides a deep insight into the global Tumour Neoantigens market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, value chain analysis, etc.

This report aims to provide a comprehensive picture of the global Tumour Neoantigens market, with both quantitative and qualitative data, to help readers understand how the Tumour Neoantigens market scenario changed across the globe during the pandemic and Russia-Ukraine War.

The base year considered for analyses is 2021, while the market estimates and forecasts are given from 2022 to 2028. The market estimates are provided in terms of revenue in USD millions and volume in K Units.

Market Segmentation:

The study segments the Tumour Neoantigens market and forecasts the market size by Type (Common Neoantigens and Individualized Neoantigens,), by Application (T Cell Adoptive Therapy, DC Therapy, Therapeutic Vaccines and Other), and region (APAC, Americas, Europe, and Middle East & Africa).

Segmentation by type

Common Neoantigens

Individualized Neoantigens

Segmentation by application

T Cell Adoptive Therapy

DC Therapy

Therapeutic Vaccines

Other

Segmentation by region

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

Major companies covered

Achilles Therapeutics plc

Advaxis Immunotherapies

Genocea

Gradalis, Inc

Gritstone bio

Iovance Biotherapeutics Inc

Medigene AG

BioNTech SE

Lilly

Scicomvisuals

Moderna, Inc

F. Hoffmann-La Roche Ltd

Merck KGaA

Sun Pharmaceutical Industries Ltd

Chapter Introduction

Chapter 1: Scope of Tumour Neoantigens, Research Methodology, etc.

Chapter 2: Executive Summary, global Tumour Neoantigens market size (sales and revenue) and CAGR, Tumour Neoantigens market size by region, by type, by application, historical data from 2017 to 2022, and forecast to 2028.

Chapter 3: Tumour Neoantigens sales, revenue, average price, global market share, and industry ranking by company, 2017-2022

Chapter 4: Global Tumour Neoantigens sales and revenue by region and by country. Country specific data and market value analysis for the U.S., Canada, Europe, China, Japan, South Korea, Southeast Asia, India, Latin America and Middle East & Africa.

Chapter 5, 6, 7, 8: Americas, APAC, Europe, Middle East & Africa, sales segment by country, by type, and type.

Chapter 9: Analysis of the current market trends, market forecast, opportunities and economic trends that are affecting the future marketplace

Chapter 10: Manufacturing cost structure analysis

Chapter 11: Sales channel, distributors, and customers

Chapter 12: Global Tumour Neoantigens market size forecast by region, by country, by type, and application.

Chapter 13: Comprehensive company profiles of the leading players, including Achilles Therapeutics plc, Advaxis Immunotherapies, Genocea, Gradalis, Inc, Gritstone bio,

lovance Biotherapeutics Inc, Medigene AG, BioNTech SE and Lilly, etc.

Chapter 14: Research Findings and Conclusion

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered

2 EXECUTIVE SUMMARY

- 2.1 World Market Overview
 - 2.1.1 Global Tumour Neoantigens Annual Sales 2017-2028
 - 2.1.2 World Current & Future Analysis for Tumour Neoantigens by Geographic Region, 2017, 2022 & 2028
 - 2.1.3 World Current & Future Analysis for Tumour Neoantigens by Country/Region, 2017, 2022 & 2028
- 2.2 Tumour Neoantigens Segment by Type
 - 2.2.1 Common Neoantigens
 - 2.2.2 Individualized Neoantigens
- 2.3 Tumour Neoantigens Sales by Type
 - 2.3.1 Global Tumour Neoantigens Sales Market Share by Type (2017-2022)
 - 2.3.2 Global Tumour Neoantigens Revenue and Market Share by Type (2017-2022)
 - 2.3.3 Global Tumour Neoantigens Sale Price by Type (2017-2022)
- 2.4 Tumour Neoantigens Segment by Application
 - 2.4.1 T Cell Adoptive Therapy
 - 2.4.2 DC Therapy
 - 2.4.3 Therapeutic Vaccines
 - 2.4.4 Other
- 2.5 Tumour Neoantigens Sales by Application
 - 2.5.1 Global Tumour Neoantigens Sale Market Share by Application (2017-2022)
 - 2.5.2 Global Tumour Neoantigens Revenue and Market Share by Application (2017-2022)
 - 2.5.3 Global Tumour Neoantigens Sale Price by Application (2017-2022)

3 GLOBAL TUMOUR NEOANTIGENS BY COMPANY

- 3.1 Global Tumour Neoantigens Breakdown Data by Company
 - 3.1.1 Global Tumour Neoantigens Annual Sales by Company (2020-2022)
 - 3.1.2 Global Tumour Neoantigens Sales Market Share by Company (2020-2022)
- 3.2 Global Tumour Neoantigens Annual Revenue by Company (2020-2022)
 - 3.2.1 Global Tumour Neoantigens Revenue by Company (2020-2022)
 - 3.2.2 Global Tumour Neoantigens Revenue Market Share by Company (2020-2022)
- 3.3 Global Tumour Neoantigens Sale Price by Company
- 3.4 Key Manufacturers Tumour Neoantigens Producing Area Distribution, Sales Area, Product Type
 - 3.4.1 Key Manufacturers Tumour Neoantigens Product Location Distribution
 - 3.4.2 Players Tumour Neoantigens Products Offered
- 3.5 Market Concentration Rate Analysis
 - 3.5.1 Competition Landscape Analysis
 - 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
- 3.6 New Products and Potential Entrants
- 3.7 Mergers & Acquisitions, Expansion

4 WORLD HISTORIC REVIEW FOR TUMOUR NEOANTIGENS BY GEOGRAPHIC REGION

- 4.1 World Historic Tumour Neoantigens Market Size by Geographic Region (2017-2022)
 - 4.1.1 Global Tumour Neoantigens Annual Sales by Geographic Region (2017-2022)
 - 4.1.2 Global Tumour Neoantigens Annual Revenue by Geographic Region
- 4.2 World Historic Tumour Neoantigens Market Size by Country/Region (2017-2022)
 - 4.2.1 Global Tumour Neoantigens Annual Sales by Country/Region (2017-2022)
 - 4.2.2 Global Tumour Neoantigens Annual Revenue by Country/Region
- 4.3 Americas Tumour Neoantigens Sales Growth
- 4.4 APAC Tumour Neoantigens Sales Growth
- 4.5 Europe Tumour Neoantigens Sales Growth
- 4.6 Middle East & Africa Tumour Neoantigens Sales Growth

5 AMERICAS

- 5.1 Americas Tumour Neoantigens Sales by Country
 - 5.1.1 Americas Tumour Neoantigens Sales by Country (2017-2022)
 - 5.1.2 Americas Tumour Neoantigens Revenue by Country (2017-2022)
- 5.2 Americas Tumour Neoantigens Sales by Type

5.3 Americas Tumour Neoantigens Sales by Application

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Tumour Neoantigens Sales by Region

6.1.1 APAC Tumour Neoantigens Sales by Region (2017-2022)

6.1.2 APAC Tumour Neoantigens Revenue by Region (2017-2022)

6.2 APAC Tumour Neoantigens Sales by Type

6.3 APAC Tumour Neoantigens Sales by Application

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 China Taiwan

7 EUROPE

7.1 Europe Tumour Neoantigens by Country

7.1.1 Europe Tumour Neoantigens Sales by Country (2017-2022)

7.1.2 Europe Tumour Neoantigens Revenue by Country (2017-2022)

7.2 Europe Tumour Neoantigens Sales by Type

7.3 Europe Tumour Neoantigens Sales by Application

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Tumour Neoantigens by Country

8.1.1 Middle East & Africa Tumour Neoantigens Sales by Country (2017-2022)

8.1.2 Middle East & Africa Tumour Neoantigens Revenue by Country (2017-2022)

- 8.2 Middle East & Africa Tumour Neoantigens Sales by Type
- 8.3 Middle East & Africa Tumour Neoantigens Sales by Application
- 8.4 Egypt
- 8.5 South Africa
- 8.6 Israel
- 8.7 Turkey
- 8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

- 9.1 Market Drivers & Growth Opportunities
- 9.2 Market Challenges & Risks
- 9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

- 10.1 Raw Material and Suppliers
- 10.2 Manufacturing Cost Structure Analysis of Tumour Neoantigens
- 10.3 Manufacturing Process Analysis of Tumour Neoantigens
- 10.4 Industry Chain Structure of Tumour Neoantigens

11 MARKETING, DISTRIBUTORS AND CUSTOMER

- 11.1 Sales Channel
 - 11.1.1 Direct Channels
 - 11.1.2 Indirect Channels
- 11.2 Tumour Neoantigens Distributors
- 11.3 Tumour Neoantigens Customer

12 WORLD FORECAST REVIEW FOR TUMOUR NEOANTIGENS BY GEOGRAPHIC REGION

- 12.1 Global Tumour Neoantigens Market Size Forecast by Region
 - 12.1.1 Global Tumour Neoantigens Forecast by Region (2023-2028)
 - 12.1.2 Global Tumour Neoantigens Annual Revenue Forecast by Region (2023-2028)
- 12.2 Americas Forecast by Country
- 12.3 APAC Forecast by Region
- 12.4 Europe Forecast by Country
- 12.5 Middle East & Africa Forecast by Country

- 12.6 Global Tumour Neoantigens Forecast by Type
- 12.7 Global Tumour Neoantigens Forecast by Application

13 KEY PLAYERS ANALYSIS

13.1 Achilles Therapeutics plc

- 13.1.1 Achilles Therapeutics plc Company Information
- 13.1.2 Achilles Therapeutics plc Tumour Neoantigens Product Offered
- 13.1.3 Achilles Therapeutics plc Tumour Neoantigens Sales, Revenue, Price and Gross Margin (2020-2022)
- 13.1.4 Achilles Therapeutics plc Main Business Overview
- 13.1.5 Achilles Therapeutics plc Latest Developments

13.2 Advaxis Immunotherapies

- 13.2.1 Advaxis Immunotherapies Company Information
- 13.2.2 Advaxis Immunotherapies Tumour Neoantigens Product Offered
- 13.2.3 Advaxis Immunotherapies Tumour Neoantigens Sales, Revenue, Price and Gross Margin (2020-2022)
- 13.2.4 Advaxis Immunotherapies Main Business Overview
- 13.2.5 Advaxis Immunotherapies Latest Developments

13.3 Genocea

- 13.3.1 Genocea Company Information
- 13.3.2 Genocea Tumour Neoantigens Product Offered
- 13.3.3 Genocea Tumour Neoantigens Sales, Revenue, Price and Gross Margin (2020-2022)
- 13.3.4 Genocea Main Business Overview
- 13.3.5 Genocea Latest Developments

13.4 Gradalis, Inc

- 13.4.1 Gradalis, Inc Company Information
- 13.4.2 Gradalis, Inc Tumour Neoantigens Product Offered
- 13.4.3 Gradalis, Inc Tumour Neoantigens Sales, Revenue, Price and Gross Margin (2020-2022)
- 13.4.4 Gradalis, Inc Main Business Overview
- 13.4.5 Gradalis, Inc Latest Developments

13.5 Gritstone bio

- 13.5.1 Gritstone bio Company Information
- 13.5.2 Gritstone bio Tumour Neoantigens Product Offered
- 13.5.3 Gritstone bio Tumour Neoantigens Sales, Revenue, Price and Gross Margin (2020-2022)
- 13.5.4 Gritstone bio Main Business Overview

- 13.5.5 Gritstone bio Latest Developments
- 13.6 lovance Biotherapeutics Inc
 - 13.6.1 lovance Biotherapeutics Inc Company Information
 - 13.6.2 lovance Biotherapeutics Inc Tumour Neoantigens Product Offered
 - 13.6.3 lovance Biotherapeutics Inc Tumour Neoantigens Sales, Revenue, Price and Gross Margin (2020-2022)
 - 13.6.4 lovance Biotherapeutics Inc Main Business Overview
 - 13.6.5 lovance Biotherapeutics Inc Latest Developments
- 13.7 Medigene AG
 - 13.7.1 Medigene AG Company Information
 - 13.7.2 Medigene AG Tumour Neoantigens Product Offered
 - 13.7.3 Medigene AG Tumour Neoantigens Sales, Revenue, Price and Gross Margin (2020-2022)
 - 13.7.4 Medigene AG Main Business Overview
 - 13.7.5 Medigene AG Latest Developments
- 13.8 BioNTech SE
 - 13.8.1 BioNTech SE Company Information
 - 13.8.2 BioNTech SE Tumour Neoantigens Product Offered
 - 13.8.3 BioNTech SE Tumour Neoantigens Sales, Revenue, Price and Gross Margin (2020-2022)
 - 13.8.4 BioNTech SE Main Business Overview
 - 13.8.5 BioNTech SE Latest Developments
- 13.9 Lilly
 - 13.9.1 Lilly Company Information
 - 13.9.2 Lilly Tumour Neoantigens Product Offered
 - 13.9.3 Lilly Tumour Neoantigens Sales, Revenue, Price and Gross Margin (2020-2022)
 - 13.9.4 Lilly Main Business Overview
 - 13.9.5 Lilly Latest Developments
- 13.10 Scicomvisuals
 - 13.10.1 Scicomvisuals Company Information
 - 13.10.2 Scicomvisuals Tumour Neoantigens Product Offered
 - 13.10.3 Scicomvisuals Tumour Neoantigens Sales, Revenue, Price and Gross Margin (2020-2022)
 - 13.10.4 Scicomvisuals Main Business Overview
 - 13.10.5 Scicomvisuals Latest Developments
- 13.11 Moderna, Inc
 - 13.11.1 Moderna, Inc Company Information
 - 13.11.2 Moderna, Inc Tumour Neoantigens Product Offered

13.11.3 Moderna, Inc Tumour Neoantigens Sales, Revenue, Price and Gross Margin (2020-2022)

13.11.4 Moderna, Inc Main Business Overview

13.11.5 Moderna, Inc Latest Developments

13.12 F. Hoffmann-La Roche Ltd

13.12.1 F. Hoffmann-La Roche Ltd Company Information

13.12.2 F. Hoffmann-La Roche Ltd Tumour Neoantigens Product Offered

13.12.3 F. Hoffmann-La Roche Ltd Tumour Neoantigens Sales, Revenue, Price and Gross Margin (2020-2022)

13.12.4 F. Hoffmann-La Roche Ltd Main Business Overview

13.12.5 F. Hoffmann-La Roche Ltd Latest Developments

13.13 Merck KGaA

13.13.1 Merck KGaA Company Information

13.13.2 Merck KGaA Tumour Neoantigens Product Offered

13.13.3 Merck KGaA Tumour Neoantigens Sales, Revenue, Price and Gross Margin (2020-2022)

13.13.4 Merck KGaA Main Business Overview

13.13.5 Merck KGaA Latest Developments

13.14 Sun Pharmaceutical Industries Ltd

13.14.1 Sun Pharmaceutical Industries Ltd Company Information

13.14.2 Sun Pharmaceutical Industries Ltd Tumour Neoantigens Product Offered

13.14.3 Sun Pharmaceutical Industries Ltd Tumour Neoantigens Sales, Revenue, Price and Gross Margin (2020-2022)

13.14.4 Sun Pharmaceutical Industries Ltd Main Business Overview

13.14.5 Sun Pharmaceutical Industries Ltd Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Tumour Neoantigens Annual Sales CAGR by Geographic Region (2017, 2022 & 2028) & (\$ millions)

Table 2. Tumour Neoantigens Annual Sales CAGR by Country/Region (2017, 2022 & 2028) & (\$ millions)

Table 3. Major Players of Common Neoantigens

Table 4. Major Players of Individualized Neoantigens

Table 5. Global Tumour Neoantigens Sales by Type (2017-2022) & (K Units)

Table 6. Global Tumour Neoantigens Sales Market Share by Type (2017-2022)

Table 7. Global Tumour Neoantigens Revenue by Type (2017-2022) & (\$ million)

Table 8. Global Tumour Neoantigens Revenue Market Share by Type (2017-2022)

Table 9. Global Tumour Neoantigens Sale Price by Type (2017-2022) & (US\$/Unit)

Table 10. Global Tumour Neoantigens Sales by Application (2017-2022) & (K Units)

Table 11. Global Tumour Neoantigens Sales Market Share by Application (2017-2022)

Table 12. Global Tumour Neoantigens Revenue by Application (2017-2022)

Table 13. Global Tumour Neoantigens Revenue Market Share by Application (2017-2022)

Table 14. Global Tumour Neoantigens Sale Price by Application (2017-2022) & (US\$/Unit)

Table 15. Global Tumour Neoantigens Sales by Company (2020-2022) & (K Units)

Table 16. Global Tumour Neoantigens Sales Market Share by Company (2020-2022)

Table 17. Global Tumour Neoantigens Revenue by Company (2020-2022) (\$ Millions)

Table 18. Global Tumour Neoantigens Revenue Market Share by Company (2020-2022)

Table 19. Global Tumour Neoantigens Sale Price by Company (2020-2022) & (US\$/Unit)

Table 20. Key Manufacturers Tumour Neoantigens Producing Area Distribution and Sales Area

Table 21. Players Tumour Neoantigens Products Offered

Table 22. Tumour Neoantigens Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)

Table 23. New Products and Potential Entrants

Table 24. Mergers & Acquisitions, Expansion

Table 25. Global Tumour Neoantigens Sales by Geographic Region (2017-2022) & (K Units)

Table 26. Global Tumour Neoantigens Sales Market Share Geographic Region

(2017-2022)

Table 27. Global Tumour Neoantigens Revenue by Geographic Region (2017-2022) & (\$ millions)

Table 28. Global Tumour Neoantigens Revenue Market Share by Geographic Region (2017-2022)

Table 29. Global Tumour Neoantigens Sales by Country/Region (2017-2022) & (K Units)

Table 30. Global Tumour Neoantigens Sales Market Share by Country/Region (2017-2022)

Table 31. Global Tumour Neoantigens Revenue by Country/Region (2017-2022) & (\$ millions)

Table 32. Global Tumour Neoantigens Revenue Market Share by Country/Region (2017-2022)

Table 33. Americas Tumour Neoantigens Sales by Country (2017-2022) & (K Units)

Table 34. Americas Tumour Neoantigens Sales Market Share by Country (2017-2022)

Table 35. Americas Tumour Neoantigens Revenue by Country (2017-2022) & (\$ Millions)

Table 36. Americas Tumour Neoantigens Revenue Market Share by Country (2017-2022)

Table 37. Americas Tumour Neoantigens Sales by Type (2017-2022) & (K Units)

Table 38. Americas Tumour Neoantigens Sales Market Share by Type (2017-2022)

Table 39. Americas Tumour Neoantigens Sales by Application (2017-2022) & (K Units)

Table 40. Americas Tumour Neoantigens Sales Market Share by Application (2017-2022)

Table 41. APAC Tumour Neoantigens Sales by Region (2017-2022) & (K Units)

Table 42. APAC Tumour Neoantigens Sales Market Share by Region (2017-2022)

Table 43. APAC Tumour Neoantigens Revenue by Region (2017-2022) & (\$ Millions)

Table 44. APAC Tumour Neoantigens Revenue Market Share by Region (2017-2022)

Table 45. APAC Tumour Neoantigens Sales by Type (2017-2022) & (K Units)

Table 46. APAC Tumour Neoantigens Sales Market Share by Type (2017-2022)

Table 47. APAC Tumour Neoantigens Sales by Application (2017-2022) & (K Units)

Table 48. APAC Tumour Neoantigens Sales Market Share by Application (2017-2022)

Table 49. Europe Tumour Neoantigens Sales by Country (2017-2022) & (K Units)

Table 50. Europe Tumour Neoantigens Sales Market Share by Country (2017-2022)

Table 51. Europe Tumour Neoantigens Revenue by Country (2017-2022) & (\$ Millions)

Table 52. Europe Tumour Neoantigens Revenue Market Share by Country (2017-2022)

Table 53. Europe Tumour Neoantigens Sales by Type (2017-2022) & (K Units)

Table 54. Europe Tumour Neoantigens Sales Market Share by Type (2017-2022)

Table 55. Europe Tumour Neoantigens Sales by Application (2017-2022) & (K Units)

- Table 56. Europe Tumour Neoantigens Sales Market Share by Application (2017-2022)
- Table 57. Middle East & Africa Tumour Neoantigens Sales by Country (2017-2022) & (K Units)
- Table 58. Middle East & Africa Tumour Neoantigens Sales Market Share by Country (2017-2022)
- Table 59. Middle East & Africa Tumour Neoantigens Revenue by Country (2017-2022) & (\$ Millions)
- Table 60. Middle East & Africa Tumour Neoantigens Revenue Market Share by Country (2017-2022)
- Table 61. Middle East & Africa Tumour Neoantigens Sales by Type (2017-2022) & (K Units)
- Table 62. Middle East & Africa Tumour Neoantigens Sales Market Share by Type (2017-2022)
- Table 63. Middle East & Africa Tumour Neoantigens Sales by Application (2017-2022) & (K Units)
- Table 64. Middle East & Africa Tumour Neoantigens Sales Market Share by Application (2017-2022)
- Table 65. Key Market Drivers & Growth Opportunities of Tumour Neoantigens
- Table 66. Key Market Challenges & Risks of Tumour Neoantigens
- Table 67. Key Industry Trends of Tumour Neoantigens
- Table 68. Tumour Neoantigens Raw Material
- Table 69. Key Suppliers of Raw Materials
- Table 70. Tumour Neoantigens Distributors List
- Table 71. Tumour Neoantigens Customer List
- Table 72. Global Tumour Neoantigens Sales Forecast by Region (2023-2028) & (K Units)
- Table 73. Global Tumour Neoantigens Sales Market Forecast by Region
- Table 74. Global Tumour Neoantigens Revenue Forecast by Region (2023-2028) & (\$ millions)
- Table 75. Global Tumour Neoantigens Revenue Market Share Forecast by Region (2023-2028)
- Table 76. Americas Tumour Neoantigens Sales Forecast by Country (2023-2028) & (K Units)
- Table 77. Americas Tumour Neoantigens Revenue Forecast by Country (2023-2028) & (\$ millions)
- Table 78. APAC Tumour Neoantigens Sales Forecast by Region (2023-2028) & (K Units)
- Table 79. APAC Tumour Neoantigens Revenue Forecast by Region (2023-2028) & (\$ millions)

Table 80. Europe Tumour Neoantigens Sales Forecast by Country (2023-2028) & (K Units)

Table 81. Europe Tumour Neoantigens Revenue Forecast by Country (2023-2028) & (\$ millions)

Table 82. Middle East & Africa Tumour Neoantigens Sales Forecast by Country (2023-2028) & (K Units)

Table 83. Middle East & Africa Tumour Neoantigens Revenue Forecast by Country (2023-2028) & (\$ millions)

Table 84. Global Tumour Neoantigens Sales Forecast by Type (2023-2028) & (K Units)

Table 85. Global Tumour Neoantigens Sales Market Share Forecast by Type (2023-2028)

Table 86. Global Tumour Neoantigens Revenue Forecast by Type (2023-2028) & (\$ Millions)

Table 87. Global Tumour Neoantigens Revenue Market Share Forecast by Type (2023-2028)

Table 88. Global Tumour Neoantigens Sales Forecast by Application (2023-2028) & (K Units)

Table 89. Global Tumour Neoantigens Sales Market Share Forecast by Application (2023-2028)

Table 90. Global Tumour Neoantigens Revenue Forecast by Application (2023-2028) & (\$ Millions)

Table 91. Global Tumour Neoantigens Revenue Market Share Forecast by Application (2023-2028)

Table 92. Achilles Therapeutics plc Basic Information, Tumour Neoantigens Manufacturing Base, Sales Area and Its Competitors

Table 93. Achilles Therapeutics plc Tumour Neoantigens Product Offered

Table 94. Achilles Therapeutics plc Tumour Neoantigens Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)

Table 95. Achilles Therapeutics plc Main Business

Table 96. Achilles Therapeutics plc Latest Developments

Table 97. Advaxis Immunotherapies Basic Information, Tumour Neoantigens Manufacturing Base, Sales Area and Its Competitors

Table 98. Advaxis Immunotherapies Tumour Neoantigens Product Offered

Table 99. Advaxis Immunotherapies Tumour Neoantigens Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)

Table 100. Advaxis Immunotherapies Main Business

Table 101. Advaxis Immunotherapies Latest Developments

Table 102. Genocea Basic Information, Tumour Neoantigens Manufacturing Base, Sales Area and Its Competitors

Table 103. Genocea Tumour Neoantigens Product Offered

Table 104. Genocea Tumour Neoantigens Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)

Table 105. Genocea Main Business

Table 106. Genocea Latest Developments

Table 107. Gradalis, Inc Basic Information, Tumour Neoantigens Manufacturing Base, Sales Area and Its Competitors

Table 108. Gradalis, Inc Tumour Neoantigens Product Offered

Table 109. Gradalis, Inc Tumour Neoantigens Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)

Table 110. Gradalis, Inc Main Business

Table 111. Gradalis, Inc Latest Developments

Table 112. Gritstone bio Basic Information, Tumour Neoantigens Manufacturing Base, Sales Area and Its Competitors

Table 113. Gritstone bio Tumour Neoantigens Product Offered

Table 114. Gritstone bio Tumour Neoantigens Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)

Table 115. Gritstone bio Main Business

Table 116. Gritstone bio Latest Developments

Table 117. Iovance Biotherapeutics Inc Basic Information, Tumour Neoantigens Manufacturing Base, Sales Area and Its Competitors

Table 118. Iovance Biotherapeutics Inc Tumour Neoantigens Product Offered

Table 119. Iovance Biotherapeutics Inc Tumour Neoantigens Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)

Table 120. Iovance Biotherapeutics Inc Main Business

Table 121. Iovance Biotherapeutics Inc Latest Developments

Table 122. Medigene AG Basic Information, Tumour Neoantigens Manufacturing Base, Sales Area and Its Competitors

Table 123. Medigene AG Tumour Neoantigens Product Offered

Table 124. Medigene AG Tumour Neoantigens Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)

Table 125. Medigene AG Main Business

Table 126. Medigene AG Latest Developments

Table 127. BioNTech SE Basic Information, Tumour Neoantigens Manufacturing Base, Sales Area and Its Competitors

Table 128. BioNTech SE Tumour Neoantigens Product Offered

Table 129. BioNTech SE Tumour Neoantigens Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)

Table 130. BioNTech SE Main Business

Table 131. BioNTech SE Latest Developments

Table 132. Lilly Basic Information, Tumour Neoantigens Manufacturing Base, Sales Area and Its Competitors

Table 133. Lilly Tumour Neoantigens Product Offered

Table 134. Lilly Tumour Neoantigens Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)

Table 135. Lilly Main Business

Table 136. Lilly Latest Developments

Table 137. Scicomvisuals Basic Information, Tumour Neoantigens Manufacturing Base, Sales Area and Its Competitors

Table 138. Scicomvisuals Tumour Neoantigens Product Offered

Table 139. Scicomvisuals Tumour Neoantigens Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)

Table 140. Scicomvisuals Main Business

Table 141. Scicomvisuals Latest Developments

Table 142. Moderna, Inc Basic Information, Tumour Neoantigens Manufacturing Base, Sales Area and Its Competitors

Table 143. Moderna, Inc Tumour Neoantigens Product Offered

Table 144. Moderna, Inc Tumour Neoantigens Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)

Table 145. Moderna, Inc Main Business

Table 146. Moderna, Inc Latest Developments

Table 147. F. Hoffmann-La Roche Ltd Basic Information, Tumour Neoantigens Manufacturing Base, Sales Area and Its Competitors

Table 148. F. Hoffmann-La Roche Ltd Tumour Neoantigens Product Offered

Table 149. F. Hoffmann-La Roche Ltd Tumour Neoantigens Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)

Table 150. F. Hoffmann-La Roche Ltd Main Business

Table 151. F. Hoffmann-La Roche Ltd Latest Developments

Table 152. Merck KGaA Basic Information, Tumour Neoantigens Manufacturing Base, Sales Area and Its Competitors

Table 153. Merck KGaA Tumour Neoantigens Product Offered

Table 154. Merck KGaA Tumour Neoantigens Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)

Table 155. Merck KGaA Main Business

Table 156. Merck KGaA Latest Developments

Table 157. Sun Pharmaceutical Industries Ltd Basic Information, Tumour Neoantigens Manufacturing Base, Sales Area and Its Competitors

Table 158. Sun Pharmaceutical Industries Ltd Tumour Neoantigens Product Offered

Table 159. Sun Pharmaceutical Industries Ltd Tumour Neoantigens Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2020-2022)

Table 160. Sun Pharmaceutical Industries Ltd Main Business

Table 161. Sun Pharmaceutical Industries Ltd Latest Developments

List Of Figures

LIST OF FIGURES

- Figure 1. Picture of Tumour Neoantigens
- Figure 2. Tumour Neoantigens Report Years Considered
- Figure 3. Research Objectives
- Figure 4. Research Methodology
- Figure 5. Research Process and Data Source
- Figure 6. Global Tumour Neoantigens Sales Growth Rate 2017-2028 (K Units)
- Figure 7. Global Tumour Neoantigens Revenue Growth Rate 2017-2028 (\$ Millions)
- Figure 8. Tumour Neoantigens Sales by Region (2021 & 2028) & (\$ millions)
- Figure 9. Product Picture of Common Neoantigens
- Figure 10. Product Picture of Individualized Neoantigens
- Figure 11. Global Tumour Neoantigens Sales Market Share by Type in 2021
- Figure 12. Global Tumour Neoantigens Revenue Market Share by Type (2017-2022)
- Figure 13. Tumour Neoantigens Consumed in T Cell Adoptive Therapy
- Figure 14. Global Tumour Neoantigens Market: T Cell Adoptive Therapy (2017-2022) & (K Units)
- Figure 15. Tumour Neoantigens Consumed in DC Therapy
- Figure 16. Global Tumour Neoantigens Market: DC Therapy (2017-2022) & (K Units)
- Figure 17. Tumour Neoantigens Consumed in Therapeutic Vaccines
- Figure 18. Global Tumour Neoantigens Market: Therapeutic Vaccines (2017-2022) & (K Units)
- Figure 19. Tumour Neoantigens Consumed in Other
- Figure 20. Global Tumour Neoantigens Market: Other (2017-2022) & (K Units)
- Figure 21. Global Tumour Neoantigens Sales Market Share by Application (2017-2022)
- Figure 22. Global Tumour Neoantigens Revenue Market Share by Application in 2021
- Figure 23. Tumour Neoantigens Revenue Market by Company in 2021 (\$ Million)
- Figure 24. Global Tumour Neoantigens Revenue Market Share by Company in 2021
- Figure 25. Global Tumour Neoantigens Sales Market Share by Geographic Region (2017-2022)
- Figure 26. Global Tumour Neoantigens Revenue Market Share by Geographic Region in 2021
- Figure 27. Global Tumour Neoantigens Sales Market Share by Region (2017-2022)
- Figure 28. Global Tumour Neoantigens Revenue Market Share by Country/Region in 2021
- Figure 29. Americas Tumour Neoantigens Sales 2017-2022 (K Units)
- Figure 30. Americas Tumour Neoantigens Revenue 2017-2022 (\$ Millions)

- Figure 31. APAC Tumour Neoantigens Sales 2017-2022 (K Units)
- Figure 32. APAC Tumour Neoantigens Revenue 2017-2022 (\$ Millions)
- Figure 33. Europe Tumour Neoantigens Sales 2017-2022 (K Units)
- Figure 34. Europe Tumour Neoantigens Revenue 2017-2022 (\$ Millions)
- Figure 35. Middle East & Africa Tumour Neoantigens Sales 2017-2022 (K Units)
- Figure 36. Middle East & Africa Tumour Neoantigens Revenue 2017-2022 (\$ Millions)
- Figure 37. Americas Tumour Neoantigens Sales Market Share by Country in 2021
- Figure 38. Americas Tumour Neoantigens Revenue Market Share by Country in 2021
- Figure 39. United States Tumour Neoantigens Revenue Growth 2017-2022 (\$ Millions)
- Figure 40. Canada Tumour Neoantigens Revenue Growth 2017-2022 (\$ Millions)
- Figure 41. Mexico Tumour Neoantigens Revenue Growth 2017-2022 (\$ Millions)
- Figure 42. Brazil Tumour Neoantigens Revenue Growth 2017-2022 (\$ Millions)
- Figure 43. APAC Tumour Neoantigens Sales Market Share by Region in 2021
- Figure 44. APAC Tumour Neoantigens Revenue Market Share by Regions in 2021
- Figure 45. China Tumour Neoantigens Revenue Growth 2017-2022 (\$ Millions)
- Figure 46. Japan Tumour Neoantigens Revenue Growth 2017-2022 (\$ Millions)
- Figure 47. South Korea Tumour Neoantigens Revenue Growth 2017-2022 (\$ Millions)
- Figure 48. Southeast Asia Tumour Neoantigens Revenue Growth 2017-2022 (\$ Millions)
- Figure 49. India Tumour Neoantigens Revenue Growth 2017-2022 (\$ Millions)
- Figure 50. Australia Tumour Neoantigens Revenue Growth 2017-2022 (\$ Millions)
- Figure 51. Europe Tumour Neoantigens Sales Market Share by Country in 2021
- Figure 52. Europe Tumour Neoantigens Revenue Market Share by Country in 2021
- Figure 53. Germany Tumour Neoantigens Revenue Growth 2017-2022 (\$ Millions)
- Figure 54. France Tumour Neoantigens Revenue Growth 2017-2022 (\$ Millions)
- Figure 55. UK Tumour Neoantigens Revenue Growth 2017-2022 (\$ Millions)
- Figure 56. Italy Tumour Neoantigens Revenue Growth 2017-2022 (\$ Millions)
- Figure 57. Russia Tumour Neoantigens Revenue Growth 2017-2022 (\$ Millions)
- Figure 58. Middle East & Africa Tumour Neoantigens Sales Market Share by Country in 2021
- Figure 59. Middle East & Africa Tumour Neoantigens Revenue Market Share by Country in 2021
- Figure 60. Egypt Tumour Neoantigens Revenue Growth 2017-2022 (\$ Millions)
- Figure 61. South Africa Tumour Neoantigens Revenue Growth 2017-2022 (\$ Millions)
- Figure 62. Israel Tumour Neoantigens Revenue Growth 2017-2022 (\$ Millions)
- Figure 63. Turkey Tumour Neoantigens Revenue Growth 2017-2022 (\$ Millions)
- Figure 64. GCC Country Tumour Neoantigens Revenue Growth 2017-2022 (\$ Millions)
- Figure 65. Manufacturing Cost Structure Analysis of Tumour Neoantigens in 2021
- Figure 66. Manufacturing Process Analysis of Tumour Neoantigens

Figure 67. Industry Chain Structure of Tumour Neoantigens

Figure 68. Channels of Distribution

Figure 69. Distributors Profiles

I would like to order

Product name: Global Tumour Neoantigens Market Growth 2022-2028

Product link: <https://marketpublishers.com/r/G976339358E0EN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G976339358E0EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970